Introduction
Sarcoidosis is a systemic inflammatory disease with unknown aetiology characterised by non-caseating granulomas with most common predilection in the hilar lymph nodes and pulmonary parenchyma. 1, 2 The spectrum of clinical symptoms of sarcoidosis is wide and related to the possible location of the lesions. 3 The clinical course and prognosis of the diseases is variable; acute forms including Lö fgren's syndrome (LS) resolve spontaneously in most cases. On the other hand, chronic pulmonary sarcoidosis may progress to the lung fibrosis and result eventually in respiratory failure.
Numerous epidemiological observations strongly evidence that sarcoidosis is a complex disease with substantial genetic (polygenic) component. Previously, the identification of genetic factors conferring susceptibility to sarcoidosis was based on case-control/family 'hypothesis-driven' studies and low density linkage scans. 4 In addition to the major histocompatibility complex genes, numerous genetic variants have been nominated as susceptibility factors or disease modifiers. 5 The first genome-wide association study (GWAS) in sarcoidosis conducted in the German population has recently revealed an association of the variants in the ANXA11 (annexin A11) gene with susceptibility to sarcoidosis. 6 This association has recently been supported by another report from the same population. 7 The aim of this work was to replicate the association of ANXA11 single nucleotide polymorphism (SNP) rs1049550 (R230C), a key coding variant associated with sarcoidosis in GWAS. 6 We wondered also whether this ANXA11 SNP might be related to the clinical manifestation of sarcoidosis. Further, the local mRNA expression of ANXA11 gene in bronchoalveolar lavage (BAL) cells was investigated in patients with sarcoidosis with distinct ANXA11 rs1049550 SNP genotypes to provide further functional data.
Results and discussion
ANXA11 rs1049550 SNP and susceptibility to sarcoidosis: replication To replicate an association between ANXA11 rs1049550 SNP and susceptibility to sarcoidosis, 245 patients with sarcoidosis and 254 healthy control subjects, all unrelated Caucasians of the Czech origin, were genotyped for this variant (Table 1 ). All subjects agreed to the anonymous usage of their biological samples for the purposes of the study, which was done with the approval of the Ethical committee of Medical Faculty and University Hospital in Olomouc, Czech Republic.
The distribution of the ANXA11 rs1049550 genotypes conformed to the Hardy-Weinberg expectations in sarcoidosis patients and healthy control subjects, (P40.05). The frequency of less common ANXA11 rs1049550*T allele in our control subjects (0.42, Table 1 ) almost equals that observed in the German population (0.41). The frequency of ANXA11 rs1049550*T allele was significantly lower in our (Czech) patients with sarcoidosis (35%) compared with the frequency observed in the control group (42%, P ¼ 0.04, odds ratio ¼ 0.77, Table 1 ). In concordance with study in German sarcoidosis patients, 6 the 'protective' effect of ANXA11*T allele increased with the number of its copies in the genotype (gene-dose effect) (Figure 1) .
Association of the ANXA11 rs1049550 SNP with clinical phenotypes of sarcoidosis In addition to replication of the principal findings from the GWAS, 6 we investigated also whether the ANXA11 rs1049550 SNP might be associated with particular clinical phenotypes of sarcoidosis, namely the chest radiographic (CXR) stages of the disease and presence of the LS. Importantly, ANXA11*T allele was less frequent in patients with the infiltration of lung parenchyma (CXR stages II-IV) compared with the patients with isolated hilar lymphadenopathy (CXR stage I, P ¼ 0.01, Figure 2 ). The 'protective' effect of ANXA11*T allele was also apparent in the subanalysis according to the presence of LS; TT homozygotes were three times more frequent among the patients with LS (21%) compared with those without LS (7%, P ¼ 0.02, odds ratio ¼ 0.31, 95% confidence interval ¼ 0.11-0.84).
Expression of ANXA11 mRNA in BAL cells of sarcoidosis patients and control subjects To reveal whether the local mRNA expression of ANXA11 is deregulated in sarcoidosis, the relative numbers of ANXA11 transcripts in BAL cells were determined in control subjects (N ¼ 14) and a subset of sarcoidosis patients (N ¼ 55) (Figure 3) . Furthermore, the controls (genotype CC, N ¼ 6; CT, N ¼ 5; TT, N ¼ 3) and sarcoidosis patients (CC, N ¼ 15; CT, N ¼ 37; TT, N ¼ 3) Figure 1 Estimated odds ratio for sarcoidosis in the carriers of one (genotype ANXA11 CT) and two (genotype ANXA11 TT) copies of ANXA11 rs1049550*T allele normalised to the CC homozygotes (odds ratio set to 1). The 'gene-dose effect' for sarcoidosis in the Czech population estimated by Cochran-Armitage trend test; P ¼ 0.035. The data for the German population were recalculated from the article by Hofmann et al. The data for the German population have been adopted from the article by Hofmann et al. The frequency of ANXA11 rs1049550*T allele in Czech patients with sarcoidosis versus control subjects: P ¼ 0.04 (odds ratio ¼ 0.77, 95% confidence interval: 0.60-0.99).
were subdivided according to the ANXA11 rs1049550 genotype.
When the expression of ANXA11 mRNA in BAL cells was compared between sarcoidosis patients and control subjects, we observed almost identical levels (P40.05, Figure 3a ). The carriers of ANXA11 rs1049550*T allele among sarcoidosis patients and control subjects appeared with slightly higher relative number of ANXA11 transcripts when compared with CC homozygotes, but this difference did not reach significance (P40.05, Figure 3b ). Annexin A11 (ANXA11) is a member of the calciumdependent, phospholipid-binding protein annexin family and its gene is located on chromosome 10q22.3. 8, 9 There have been several functions suggested for ANXA11 in calcium signalling, cell division, apoptosis and exocytotic pathway. 10 Nevertheless, the data on the role of ANXA11 in human diseases have been limited; for example elevated ANXA11 protein levels were reported in colorectal cancer tissue correlated with tumour stage and poorer survival. 11 Autoantibodies against ANXA11 (identical to the '56K autoantigen') were identified in patients with autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis and antiphospholipid syndrome. 12, 13 However, no relationship between ANXA11 gene variants and any immune-mediated disease was revealed nor suggested before it was nominated by the first GWAS in sarcoidosis. 6 In the present study we replicated contribution of ANXA11 rs1049550 SNP to the genetic susceptibility to sarcoidosis. Particularly, the ANXA11 rs1049550*T variant was associated with protection from sarcoidosis and the level of protection has been shown to depend on the number T alleles in the genotype (gene-dose effect). Furthermore, the T allele carriers among the patients were protected from infiltration of lung parenchyma (radiographic stages II-IV). Further, TT genotype was overrepresented in patients with Lö fgren's syndrome, a phenotype with good prognosis. Besides the role as a susceptibility marker in sarcoidosis, we therefore nominated ANXA11 rs1049550 SNP as a phenotype modifier of the disease.
In our experiments aimed at local ANXA11 mRNA expression in BAL cells we did not observe any difference between the patients with sarcoidosis and control subjects, which is in line with the preliminary data reported in the GWAS study. 6 Furthermore, ANXA11 mRNA expression in BAL cells was neither significantly affected by the carriage of rs1049550*T allele in our patients with sarcoidosis nor in control subjects. In regard to the possible mechanism by which rs1049550 SNP affects the susceptibility to sarcoidosis or its manifestation, one may therefore postulate that this coding variant changes the functional properties of ANXA11 protein rather than affects its quantitative expression. In this respect, rs1049550 SNP results in the switch of a basic arginine to a polar cysteine at position 230 within a highly conserved ANXA11 domain responsible for the calcium-binding properties. However, the wild-type ANXA11 protein and its R230C variant did not differ in terms of sensitivity to Ca2 þ in the recent study.
14 Besides a role in calcium signalling, annexin A11 has been implicated in apoptosis and vesicle trafficking, 8 cell growth, 10 survival of cancer cells 11 and terminal phase of cell division. 15 In this context, the development and maintenance of granulomatous inflammation in sarcoidosis have repeatedly been associated with impaired apoptosis of activated inflammatory cells. [16] [17] [18] Stridh et al. 17 revealed that BAL lymphocytes from patients with sarcoidosis were less sensitive to apoptotic stimuli than those from control subjects in vitro (as assessed by annexin A5 positivity). Similarly, peripheral blood monocytes from sarcoidosis patients were characterised by an apoptosis-resistant phenotype in another study. 18 Furthermore, the changes in BAL fluid levels of another member of the annexin family (annexin A2) in sarcoi- . The data are presented as mean relative ANXA11 expression with standard deviation normalised to a reference PSMB2 gene. 23 No significant difference in the ANXA11 expression was observed between the groups (P40.05). Methods in brief: BAL was performed according to a standard procedure 24 in 55 patients with pulmonary sarcoidosis (21 males/34 females; CXRstage I, N ¼ 18; stage II, N ¼ 28; stage III-IV, N ¼ 9) and 14 control subjects of Czech origin. The control group consisted of subjects (eight males/six females) undergoing BAL as part of clinical investigation. All controls had normal BAL fluid cytology, immunology, microbiology and CD4 þ /CD8 þ ratio. No subject received corticosteroid treatment before BAL. BAL cells were separated from the fluid by centrifugation as described elsewhere. 25 Total RNA from unseparated BAL cells was isolated with mirVana miRNA kit (Ambion, Austin, TX, USA); reverse transcription was performed with Reverse-iT RTase Blend using anchored dT primers (ABgene, Epsom, UK) according to the manufacturer's instructions. Primers (5 0 -ttgaacttggactcgtctgttc-3 0 , 5 0 -actcgcccagagagatgc-3 0 ) and probe (UPL probe #17, Roche Applied Science, Indianapolis, IN, USA) to investigate the ANXA11 gene expression were designed using ProbeFinder assay design tool to cover all three known ANXA11 transcript variants a, b, c (http://www.universalprobelibrary.com). PCR reactions were performed on RotorGene3000 system (Corbett Research, Sydney, NSW, Australia) as described previously. 23 The relative expression was calculated by a second-derivative method (RotorGene Software 6.1.81, Corbett Research); cDNA from human universal reference RNA (Stratagene, La Jolla, CA, USA) was used as a calibrator and PSMB2 as a reference gene.
23
ANXA11 gene variant in sarcoidosis F Mrazek et al dosis has recently been reported using a proteomic approach. 19 These observations allow us to speculate that particular functional variants of annexin A11 (for example, ANXA11 R230C) may affect sensitivity of inflammatory cells to apoptosis and thus confer differences in susceptibility to sarcoidosis and its clinical course. Because virtually no data directly supportive for this idea are available at present, the involvement of annexin A11 protein and its variants in cell survival, proliferation and apoptosis in sarcoidosis lesions should be investigated in future studies.
Concerning alternative explanations of the relationship between the ANXA11 rs1049550 SNP and genetic susceptibility to sarcoidosis, one may speculate that structural change in the variant ANXA11 protein may modify its autoantigenic properties, 13, 20 and by this way interfere with the granulomatous inflammation in sarcoidosis. It is important to note, that an association of ANXA11 gene variant with sarcoidosis, albeit confirmed, does not necessarily imply annexin A11 protein and its structural variation in the pathogenesis and clinical manifestation of this disorder. There is still a possibility that the rs1049550 SNP is just a marker of a haplotype possessing causative variant(s) or that this haplotype acts as a whole. 6 In this context, the data on ANXA11 genetic variation and expression in sarcoidosis from other major ethnic groups are highly desirable. 21 
Conclusions
In the Czech population, we replicate consistently the relationship of ANXA11 rs1049550 SNP with sarcoidosis observed originally in the German GWAS. ANXA11 rs1049550*T allele is, therefore, associated directly or via linkage with causative variant with protection from sarcoidosis, at least in Central European Caucasians. Based on our subanalyses, we also nominated ANXA11 rs1049550*T variant as a marker of protection from infiltration of lung parenchyma. The quantitative mRNA expression of ANXA11 in BAL cells is not deregulated in sarcoidosis and does not correlate with the rs1049550 genotypes. Therefore, the mechanism by which ANXA11 and its gene variants implicate in the development/ pathogenesis of sarcoidosis will undoubtedly be in the scope of further research.
